JHX

LONG

JAMES HARDIE INDS PLC

Funds

Score

4.00

vs SPY

+6.6%

Stock return (since Q-end)

+22.9%

SPY return (since Q-end)

+16.3%

Current price

$23.28

News Summary

Neutral

James Hardie delivered FY26 results with strong adjusted EBITDA growth (+17% YoY to $1.27B) and beat Q4 guidance, but underlying organic sales declined 1-2% amid persistent North American housing market weakness. The controversial AZEK acquisition is executing ahead of schedule on synergies ($125M revenue run-rate targeted), though net leverage climbed to $4.49B debt and FY27 guidance assumes no market recovery, with confidence resting entirely on operational execution rather than demand tailwinds.

Red flags

•Organic sales declined 1-2% despite 45% reported Q4 growth (entirely acquisition-driven)
•GAAP net income collapsed 75% YoY to $104M from $424M due to acquisition and asbestos costs
•Net leverage elevated at ~3.5x post-AZEK; management must reduce to 2.0x by Q2 FY28
•No demand recovery assumed in FY27 guidance—confidence hinges on synergies and cost-cutting, not market improvement
•Q4 GAAP net income fell 35% despite revenue beat, signaling margin compression from non-recurring charges
•Barclays cut price target 23% (from $26 to $21) citing demand softness and valuation concerns

Funds Buying (3)

Fund	Manager	Shares Held	∆ Shares	Position Value	QoQ	Status
D1 Capital	Dan Sundheim	28.3M	+3.9M	$536.0B	+16%	Existing
Point72	Steve Cohen	6.3M	+6.3M	$118.9B	—	NEW
Maverick Capital	Lee Ainslie	36K	+36K	$673M	—	NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.